Summit Therapeutics SMMT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.21B-11.7% | -$1.08B-17.1% | -$921.62M-23.5% | -$746.08M-210% | -$240.76M-8.8% | ||
| $165K+13.0% | $146K+15.9% | $126K+21.2% | $104K+19.5% | $87K-2.2% | ||
| $794.12M+8.4% | $732.42M+16.0% | $631.66M+21.4% | $520.27M+890% | $52.57M+3.1% | ||
| —— | —— | —— | —— | —— | ||
| $23.54M+82.0% | $12.93M+33.6% | $9.68M-33.8% | $14.63M-7.0% | $15.72M+32.3% | ||
| -$5.26M-8.1% | -$4.87M-134% | $14.35M+6.5% | $13.48M+20.0% | $11.24M+52.4% | ||
| $24K-70.7% | $82K-23.4% | $107K+5.9% | $101K— | —— | ||
| -$384.05M-18.9% | -$322.93M-19.8% | -$269.67M-30.3% | -$206.88M-19.5% | -$173.14M-21.8% | ||
| $480K-26.9% | $657K+29.6% | $507K+2.6% | $494K-11.3% | $557K+301% | ||
| $662.28M+36.6% | $484.99M+224% | $149.49M-52.8% | $317.04M-46.0% | $587.05M-13.7% | ||
| —— | —— | —— | $618.32M+15.0% | $537.51M+9.7% | ||
| -$334.66M-92.0% | -$174.31M— | —— | —— | —— | ||
| $7.43M+31.5% | $5.65M+10.2% | $5.13M-3.6% | $5.32M+11.9% | $4.76M+73.8% | ||
| $613.65M-0.6% | $617.53M+1,313% | $43.71M-79.6% | $214.04M-48.1% | $412.03M+1.8% | ||
| —— | —— | $13K-87.6% | $105K— | —— | ||
| —— | —— | —— | $269.44M+79.3% | $150.23M+345% | ||
| $8.26M+17.9% | $7.01M— | —— | —— | —— | ||
| $165K+13.0% | $146K+15.9% | $126K+21.2% | $104K+19.5% | $87K-2.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.64M-125% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $24K-70.7% | $82K-23.4% | $107K+5.9% | $101K— | —— | ||
| $8M+264% | -$4.87M-204% | $4.67M-45.0% | $8.5M+147% | $3.45M-53.3% | ||
| $662.28M+36.6% | $484.99M+224% | $149.49M-52.8% | $317.04M-46.0% | $587.05M-13.7% | ||
| —— | —— | —— | $618.32M+15.0% | $537.51M+9.7% | ||
| $7.43M+31.5% | $5.65M+10.2% | $5.13M+8.6% | $4.72M+10.6% | $4.27M+56.1% | ||
| —— | —— | —— | $7.81M+24.9% | $6.26M+946% | ||
| $1.04M+256% | $291K+77.4% | $164K+128% | $72K— | —— | ||
| -$384.53M-18.8% | -$323.59M-19.8% | -$270.17M-30.3% | -$207.38M-19.4% | -$173.7M-22.1% | ||
| -$384.53M-18.8% | -$323.59M-19.8% | -$270.17M-30.3% | -$207.38M-19.4% | -$173.7M-22.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.